diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12487diaendo-12487Research ArticleОбзорыReviewСовременные данные об эффективности гликлазида и молекулярные механизмы действия препаратаCurrent data on the effectiveness of gliclazide and molecular mechanisms of action of the drughttps://orcid.org/0000-0001-9390-1200ПетунинаНина АлександровнаPetuninaNina A.

Доктор медицинских наук, профессор, член-корреспондент РАН, eLibrary SPIN: 9784-3616

Prof., MD, PhD, eLibrary SPIN: 9784-3616

napetunina@mail.ruКузинаИрина АлександровнаKuzinaIrina A.

eLibrary SPIN: 9008-5886

119435 Москва, ул. Большая Пироговская, д. 2, стр. 4

eLibrary SPIN: 9008-5886

2-4 Bolshaya Pirogovskaya, 119435 Moscow

mia986@mail.ruhttps://orcid.org/0000-0002-6823-2487НедосуговаЛюдмила ВикторовнаNedosugovaLudmila V.

Доктор медицинских наук, доцент, eLibrary SPIN: 1853-0215

MD, PhD, associate professor, eLibrary SPIN: 1853-0215

profmila@mail.ruПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202002122020234357367Copyright © Петунина Н.А., Кузина И.А., Недосугова Л.В., 20202020Петунина Н.А., Кузина И.А., Недосугова Л.В.Petunina N.A., Kuzina I.A., Nedosugova L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12487

Учитывая растущую распространенность сахарного диабета 2 типа (СД2), одним из главных вопросов является возможность его лечения доступными препаратами. Несмотря на то что гликемический контроль и уменьшение микро- и макрососудистых осложнений остаются важными аспектами лечения, доступность и стоимость пероральных сахароснижающих препаратов являются основными ограничивающими факторами. И хотя более новые препараты, такие как ингибиторы натриево-глюкозного котранспортера 2, ингибиторы дипептидилпептидазы-4 и агонисты рецепторов глюкагоноподобного пептида 1, имеют преимущества у пациентов с инсулинорезистентностью и сердечно-сосудистыми осложнениями, они относительно дороги и имеют ограниченную доступность. Производные сульфонилмочевины (ПСМ) второго поколения эффективно снижают уровень гликированного гемоглобина, способствуют профилактике микро- и макрососудистых осложнений СД2. В обзоре обосновывается роль гликлазида МВ 60 мг как более доступного препарата для лечения СД2, безопасность которого подтверждена многими исследованиями; показаны кардио-, нефропротективный эффекты, а также разбираются уникальные механизмы влияния препарата на в-клетки поджелудочной железы и экстрапанкреатические эффекты через активацию фосфолипазы С и рецепторы, связанные с G-белком. Представлены последние данные по оценке неблагоприятных явлений гликлазида МВ в сравнении как с другими ПСМ, так и с сахароснижающими препаратами иных классов.

With the growing prevalence of type 2 diabetes mellitus (T2DM) the possibility of treating it with available drugs is one of the main issues. Although glycemic control and reduction of micro- and macrovascular outcomes remain important aspects of treatment, the main limiting factors are the availability and cost of oral hypoglycemic agents. Although newer agents, such as sodium -glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists, potentially being valuable for patients with insulin resistance and cardiovascular complications, they are relatively expensive and have limited availability. Second-generation sulfonylureas effectively reduce glycated hemoglobin and contribute to the prevention of micro- and macrovascular complications of T2DM The review substantiates the role of Gliclazide MR as a more affordable drug for the treatment of T2DM, the safety of which has been confirmed by many studies; cardio-and nephroprotective effects are shown, as well as mechanisms for influencing в-cells of the pancreas and extrapancreatic effects through activation of phospholipase C and the G-protein-сoupled-receptors (GPCR) are analyzed. The latest data on the assessment of adverse events of Gliclazide MR are presented in comparison with both other sulfonylureas and glucose-lowering drugs of other classes.

сахарный диабет 2 типагликемический контрольгликлазид МВфосфолипаза Сэффективностьбезопасностьнеблагоприятные явлениядоступностьtype 2 diabetes mellitusglycaemic controlgliclazide MRphospholipase Ceffectivenesssafetyadverse eventsavailabilityПоиск и анализ литературы проводился авторами без привлечения внешних источников финансирования, спонсорской или иной поддержки. При редактировании рукописи использована финансовая поддержка компании Servier, при этом компания не оказывала влияния на содержание рукописиReferencesWorld Health Organization. Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. World Health Organization; 2018. Available from: https://apps.who.int/iris/handle/10665/272433World Health Organization. Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. World Health Organization; 2018. Available from: https://apps.who.int/iris/handle/10665/272433IDF Diabetes Atlas. 9th Edition. Brussels: International Diabetes Federation; 2019. Available from: https://diabetesatlas.org/en/IDF Diabetes Atlas. 9th Edition. Brussels: International Diabetes Federation; 2019. Available from: https://diabetesatlas.org/en/Wu Y, Ding Y, Tanaka Y, Zhang W, Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J MedSci. 2014;11(11):1185-200. doi: https://doi.org/10.7150/ijms.10001Wu Y, Ding Y, Tanaka Y, Zhang W, Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J MedSci. 2014;11(11):1185-200. doi: https://doi.org/10.7150/ijms.10001NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513-1530. doi: https://doi.org/10.1016/S0140-6736(16)00618-8NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513-1530. doi: https://doi.org/10.1016/S0140-6736(16)00618-8Shrivastava U, Misra A. Need for ethnic-specific guidelines for prevention, diagnosis, and manage- ment of type 2 diabetes in South Asians. Diabetes Technol Ther. 2015;17(6):435-439. doi: https://doi.org/10.1089/dia.2014.0213Shrivastava U, Misra A. Need for ethnic-specific guidelines for prevention, diagnosis, and manage- ment of type 2 diabetes in South Asians. Diabetes Technol Ther. 2015;17(6):435-439. doi: https://doi.org/10.1089/dia.2014.0213Shrivastava U, Misra A, Gupta R, Viswanathan V. Socioeconomic factors relating to diabetes and its management in India. J Diabetes. 2016;8(1):12-23. doi: https://doi.org/10.1111/1753-0407.12316Shrivastava U, Misra A, Gupta R, Viswanathan V. Socioeconomic factors relating to diabetes and its management in India. J Diabetes. 2016;8(1):12-23. doi: https://doi.org/10.1111/1753-0407.12316Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi: https://doi.org/10.2337/dci18-0033Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi: https://doi.org/10.2337/dci18-0033American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90-102. doi: https://doi.org/10.2337/dc19-S009American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90-102. doi: https://doi.org/10.2337/dc19-S009Libianto R, Ekinci EI. New agents for the treatment of type 2 diabetes. Crit Care Clin. 2019;35(2):315-328. doi: https://doi.org/10.1016Zj.ccc.2018.11.007Libianto R, Ekinci EI. New agents for the treatment of type 2 diabetes. Crit Care Clin. 2019;35(2):315-328. doi: https://doi.org/10.1016Zj.ccc.2018.11.007Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633-644. doi: https://doi.org/10.1056/NEJMoa1800256Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633-644. doi: https://doi.org/10.1056/NEJMoa1800256Mohan V, Khunti K, Chan SP et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther. 2020;11(1):15-35. doi: https://doi.org/10.1007/s13300-019-00733-9Mohan V, Khunti K, Chan SP et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther. 2020;11(1):15-35. doi: https://doi.org/10.1007/s13300-019-00733-9Owolabi MO, Yaria JO, Daivadanam M, et al. Gaps in guidelines for the management of diabetes in low- and middle-income versus high-income countries - a systematic review. Diabetes Care. 2018;41(5):1097-1105. doi: https://doi.org/10.2337/dc17-1795Owolabi MO, Yaria JO, Daivadanam M, et al. Gaps in guidelines for the management of diabetes in low- and middle-income versus high-income countries - a systematic review. Diabetes Care. 2018;41(5):1097-1105. doi: https://doi.org/10.2337/dc17-1795The Lancet Diabetes & Endocrinology. Forging paths to improve diabetes care in low-income settings. Lancet Diabetes Endocrinol. 2017;5(8):565. doi: https://doi.org/10.1016/S2213-8587(17)30230-9The Lancet Diabetes & Endocrinology. Forging paths to improve diabetes care in low-income settings. Lancet Diabetes Endocrinol. 2017;5(8):565. doi: https://doi.org/10.1016/S2213-8587(17)30230-9Desai U, Kirson NY, Kim J, et al. Time to treatment intensification after monotherapy failure and its association with subsequent glycemic control among 93,515 patients with type 2 diabetes. Diabetes Care. 2018;41(10):2096-2104. doi: https://doi.org/10.2337/dc17-0662Desai U, Kirson NY, Kim J, et al. Time to treatment intensification after monotherapy failure and its association with subsequent glycemic control among 93,515 patients with type 2 diabetes. Diabetes Care. 2018;41(10):2096-2104. doi: https://doi.org/10.2337/dc17-0662Аметов А.С., Черникова Н.А., Кнышенко О.А. Роль и место препаратов сульфонилмочевины в современном управлении сахарным диабетом типа 2 // Эндокринология: Новости. Мнения. Обучение. — 2019. — Т. 8. — №1. — С. 40-48. doi: https://doi.org/10.24411/2304-9529-2019-11005Ametov AS, Chernikova NA, Knyshenko OA. Sulfonylureas: the role and place of drugs in the management of type 2 diabetes mellitus. Endocrinology: news, opinions, training. 2019;8(1):40-48. (In Russ.). doi: https://doi.org/10.24411/2304-9529-2019-11005Sola D, Rossi L, Schianca GP et al. Sulfonylureas and their use in clinical practice. Archives of Medical Science. 2015;11(4):840-848. doi: https://doi.org/10.5114/aoms.2015.53304Sola D, Rossi L, Schianca GP et al. Sulfonylureas and their use in clinical practice. Archives of Medical Science. 2015;11(4):840-848. doi: https://doi.org/10.5114/aoms.2015.53304Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325(5940):607-610. doi: https://doi.org/10.1126/science.1172256Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325(5940):607-610. doi: https://doi.org/10.1126/science.1172256Gloerich M, Bos JL. Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol. 2010;50:355-375. doi: https://doi.org/10.1146/annurev.pharmtox.010909.105714Gloerich M, Bos JL. Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol. 2010;50:355-375. doi: https://doi.org/10.1146/annurev.pharmtox.010909.105714Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A. 2007;104(49):19333-19338. doi: https://doi.org/10.1073/pnas.0707054104Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A. 2007;104(49):19333-19338. doi: https://doi.org/10.1073/pnas.0707054104Dzhura I, Chepurny OG, Leech CA, et al. Phospholipase C-e links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. Islets. 2011;3(3):121-128. doi: https://doi.org/10.4161/isl.33.15507Dzhura I, Chepurny OG, Leech CA, et al. Phospholipase C-e links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. Islets. 2011;3(3):121-128. doi: https://doi.org/10.4161/isl.33.15507Jarrard RE, Wang Y, Salyer AE, et al. Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx. Mol Pharmacol. 2013;83(1):191-205. doi: https://doi.org/10.1124/mol.112.081943Jarrard RE, Wang Y, Salyer AE, et al. Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx. Mol Pharmacol. 2013;83(1):191-205. doi: https://doi.org/10.1124/mol.112.081943Takahashi T, Shibasaki T, Takahashi H, et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013;6(298):ra94. doi: https://doi.org/10.1126/scisignal.2004581Takahashi T, Shibasaki T, Takahashi H, et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013;6(298):ra94. doi: https://doi.org/10.1126/scisignal.2004581Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig. 2014;5(5):475-477. doi: https://doi.org/10.1111/jdi.12229Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig. 2014;5(5):475-477. doi: https://doi.org/10.1111/jdi.12229Colagiuri S, Matthews D, Leiter LA, et al. The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract. 2018;143:1-14. doi: https://doi.org/10.1016/j.diabres.2018.05.028Colagiuri S, Matthews D, Leiter LA, et al. The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract. 2018;143:1-14. doi: https://doi.org/10.1016/j.diabres.2018.05.028Hayward RA, Reaven PD, Wiitala WL, et al. Follow- up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197-2206. doi: https://doi.org/10.1056/NEJMoa1414266Hayward RA, Reaven PD, Wiitala WL, et al. Follow- up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197-2206. doi: https://doi.org/10.1056/NEJMoa1414266Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56(5):973-984. doi: https://doi.org/10.1007/s00125-013-2856-6Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56(5):973-984. doi: https://doi.org/10.1007/s00125-013-2856-6Mamza J, Mehta R, Donnelly R, Idris I. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Ann Med. 2016;48(4):224-234. doi: https://doi.org/10.3109/07853890.2016.115726Mamza J, Mehta R, Donnelly R, Idris I. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Ann Med. 2016;48(4):224-234. doi: https://doi.org/10.3109/07853890.2016.115726Mohan V, Anjana RM, Ranjit U, et al. Clinical profile of elderly patients (over 90 years) with type 2 diabetes seen at a diabetes centre in South India. Diabetes Technol Ther. 2019;22(2):79-84. doi: https://doi.org/10.1089/dia.2019.0219Mohan V, Anjana RM, Ranjit U, et al. Clinical profile of elderly patients (over 90 years) with type 2 diabetes seen at a diabetes centre in South India. Diabetes Technol Ther. 2019;22(2):79-84. doi: https://doi.org/10.1089/dia.2019.0219Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254-2261. doi: https://doi.org/10.2337/dc13-0356Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254-2261. doi: https://doi.org/10.2337/dc13-0356Khunti K, Chatterjee S, Gerstein HC, et al. Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol. 2018;6(10):821-832. doi: https://doi.org/10.1016/S2213-8587(18)30025-1Khunti K, Chatterjee S, Gerstein HC, et al. Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol. 2018;6(10):821-832. doi: https://doi.org/10.1016/S2213-8587(18)30025-1Simpson SH, Lee J, Choi S, et al. Mortality risk among sulfonylureas: a systematic review and network metaanalysis. Lancet Diabetes Endocrinol. 2015;3(1):43-51. doi: https://doi.org/10.1016/S2213-8587(14)70213-XSimpson SH, Lee J, Choi S, et al. Mortality risk among sulfonylureas: a systematic review and network metaanalysis. Lancet Diabetes Endocrinol. 2015;3(1):43-51. doi: https://doi.org/10.1016/S2213-8587(14)70213-XPalmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316(3):313-324. doi: https://doi.org/10.1001/jama.2016.9400Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316(3):313-324. doi: https://doi.org/10.1001/jama.2016.9400Qian D, Zhang T, Zheng P, et al. Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: a network meta-analysis. Diabetes Ther. 2018;9(5):1945-1958. doi: https://doi.org/10.1007/s13300-018-0482-5Qian D, Zhang T, Zheng P, et al. Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: a network meta-analysis. Diabetes Ther. 2018;9(5):1945-1958. doi: https://doi.org/10.1007/s13300-018-0482-5Webb DR, Davies MJ, Jarvis J, et al. The right place for sulphonylureas today. Part of review the series: Implications of recent CVOTs in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019;157:107836. doi: https://doi.org/10.1016/j.diabres.2019.107836Webb DR, Davies MJ, Jarvis J, et al. The right place for sulphonylureas today. Part of review the series: Implications of recent CVOTs in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019;157:107836. doi: https://doi.org/10.1016/j.diabres.2019.107836American Diabetes Association. Linagliptin and glimepiride have comparable cardiovascular safety effects in type 2 diabetes at high cardiovascular risk. San Francisco, California; 2019. Available from: http://www.diabetes.org/newsroom/press-releases/2019/linagliptin-and-glimepiride.htmlAmerican Diabetes Association. Linagliptin and glimepiride have comparable cardiovascular safety effects in type 2 diabetes at high cardiovascular risk. San Francisco, California; 2019. Available from: http://www.diabetes.org/newsroom/press-releases/2019/linagliptin-and-glimepiride.htmlVaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-897. doi: https://doi.org/10.1016/S2213-8587(17)30317-0Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-897. doi: https://doi.org/10.1016/S2213-8587(17)30317-0Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517-523. doi: https://doi.org/10.1038/ki.2012.401Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517-523. doi: https://doi.org/10.1038/ki.2012.401Navarro G, Xu W, Jacobson DA, et al. Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. Cell Metab. 2016;23(5):837-851. doi: https://doi.org/10.1016/j.cmet.2016.03.015Navarro G, Xu W, Jacobson DA, et al. Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. Cell Metab. 2016;23(5):837-851. doi: https://doi.org/10.1016/j.cmet.2016.03.015Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov. 2012;11(8):603-619. doi: https://doi.org/10.1038/nrd3777Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov. 2012;11(8):603-619. doi: https://doi.org/10.1038/nrd3777Marselli L, Thorne J, Dahiya S, et al. Gene expression profiles of beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One. 2010;5(7):e11499. doi: https://doi.org/10.1371/journal.pone.0011499Marselli L, Thorne J, Dahiya S, et al. Gene expression profiles of beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One. 2010;5(7):e11499. doi: https://doi.org/10.1371/journal.pone.0011499Jarrard RE, Wang Y, Salyer AE, et al. Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx. Mol Pharmacol. 2013;83(1):191-205. doi: https://doi.org/10.1124/mol.112.081943Jarrard RE, Wang Y, Salyer AE, et al. Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx. Mol Pharmacol. 2013;83(1):191-205. doi: https://doi.org/10.1124/mol.112.081943Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract. 2005;70(3):291-297. doi: https://doi.org/10.1016/j.diabres.2005.04.002Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract. 2005;70(3):291-297. doi: https://doi.org/10.1016/j.diabres.2005.04.002J0rgensen CH, Gislason GH, Andersson C, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54. doi: https://doi.org/10.1186/1475-2840-9-54J0rgensen CH, Gislason GH, Andersson C, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54. doi: https://doi.org/10.1186/1475-2840-9-54Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32(15):1900-1908. doi: https://doi.org/10.1093/eurheartj/ehr077Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32(15):1900-1908. doi: https://doi.org/10.1093/eurheartj/ehr077Li L, Renier G. The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis inhuman aortic endothelial cells. Atherosclerosis. 2009;204(1):40-46. doi: https://doi.org/10.1016/j.atherosclerosis.2008.08.008Li L, Renier G. The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis inhuman aortic endothelial cells. Atherosclerosis. 2009;204(1):40-46. doi: https://doi.org/10.1016/j.atherosclerosis.2008.08.008Renier G, Mamputu JC, Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism. 2003;52(8 Suppl 1):13-18. doi: https://doi.org/10.1016/s0026-0495(03)00212-9Renier G, Mamputu JC, Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism. 2003;52(8 Suppl 1):13-18. doi: https://doi.org/10.1016/s0026-0495(03)00212-9Muller G. The molecular mechanism of the insulin-mimetic/ sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol Med. 2000;6(11):907-933.Muller G. The molecular mechanism of the insulin-mimetic/ sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol Med. 2000;6(11):907-933.Roduguez E, Pulido N, Romero R, et al. Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle. Endocrinology. 2004;145(2):679-185. doi: https://doi.org/10.1210/en.2003-0755Roduguez E, Pulido N, Romero R, et al. Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle. Endocrinology. 2004;145(2):679-185. doi: https://doi.org/10.1210/en.2003-0755Toker A, Cantley LC. Signaling through the lipid products of phospho-inositide-3-OH-kinase. Nature. 1997;387(6634):673-676. doi: https://doi.org/10.1038/42648Toker A, Cantley LC. Signaling through the lipid products of phospho-inositide-3-OH-kinase. Nature. 1997;387(6634):673-676. doi: https://doi.org/10.1038/42648Pulido N, Romero R, Suarez A, et al. Sulfonylureas stimulate glucose uptake through GLUT4 transporter translocation in rat skeletal muscle. Biochem Biophys Res Commun. 1996;228(2):499-504. doi: https://doi.org/10.1006/bbrc.1996.1689Pulido N, Romero R, Suarez A, et al. Sulfonylureas stimulate glucose uptake through GLUT4 transporter translocation in rat skeletal muscle. Biochem Biophys Res Commun. 1996;228(2):499-504. doi: https://doi.org/10.1006/bbrc.1996.1689Pulido N, Sua'rez A, Casanova B, et al. Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle. Metabolism. 1997;46(12 Suppl 1):10-13. doi: https://doi.org/10.1016/s0026-0495(97)90310-3Pulido N, Sua'rez A, Casanova B, et al. Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle. Metabolism. 1997;46(12 Suppl 1):10-13. doi: https://doi.org/10.1016/s0026-0495(97)90310-3Sekiya F, Bae YS, Rhee SG. Regulation of phospholipase C isozymes: activation of phospholipase C-y in the absence of tyrosine-phosphorylation. Chem Phys Lipids. 1999;98(1-2):3-11. doi: https://doi.org/10.1016/s0009-3084(99)00013-4Sekiya F, Bae YS, Rhee SG. Regulation of phospholipase C isozymes: activation of phospholipase C-y in the absence of tyrosine-phosphorylation. Chem Phys Lipids. 1999;98(1-2):3-11. doi: https://doi.org/10.1016/s0009-3084(99)00013-4Nakamura Y, Fukami K. Regulation and physiological functions of mammalian phospholipase C. J Biochem. 2017;161(4):315-321. doi: https://doi.org/10.1093/jb/mvw094Nakamura Y, Fukami K. Regulation and physiological functions of mammalian phospholipase C. J Biochem. 2017;161(4):315-321. doi: https://doi.org/10.1093/jb/mvw094Qiu Y, Ping P, Tang XL, et al. Direct evidence that protein kinase C plays an essential role in the development of late preconditioning against myocardial stunning in conscious rabbits and that is the isoform involved. J Clin Invest. 1998;101(10)2182-2198. doi: https://doi.org/10.1172/JCI1258Qiu Y, Ping P, Tang XL, et al. Direct evidence that protein kinase C plays an essential role in the development of late preconditioning against myocardial stunning in conscious rabbits and that is the isoform involved. J Clin Invest. 1998;101(10)2182-2198. doi: https://doi.org/10.1172/JCI1258Liu GS, Cohen MV, Monchly-Rosen D, Downey JM. Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocyte. J Mol Cell Cardiol. 1999;31(10):1937-1948. doi: https://doi.org/10.1006/jmcc.1999.1026Liu GS, Cohen MV, Monchly-Rosen D, Downey JM. Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocyte. J Mol Cell Cardiol. 1999;31(10):1937-1948. doi: https://doi.org/10.1006/jmcc.1999.1026Goffart S, von Kleist-Retzow JC, Wiesner RJ. Regulation of mitochondrial proliferation in the heart: powerplant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res. 2004;64(2):198-207. doi: https://doi.org/10.1016/jcarcliores2004.06.030Goffart S, von Kleist-Retzow JC, Wiesner RJ. Regulation of mitochondrial proliferation in the heart: powerplant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res. 2004;64(2):198-207. doi: https://doi.org/10.1016/jcarcliores2004.06.030Ochocka AM, Pawelczyk T. Isozymes 5 of phosphoinositide-specific phospholipase C and their role in signal transduction in the cell. Acta Biochim Pol. 2003;50(4):1097-1110.Ochocka AM, Pawelczyk T. Isozymes 5 of phosphoinositide-specific phospholipase C and their role in signal transduction in the cell. Acta Biochim Pol. 2003;50(4):1097-1110.Brookes PS, Yoon Y, Robotham JL, et al. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol. 2004;287(4):C817-833. doi: https://doi.org/10.1152/ajpcell.00139.2004Brookes PS, Yoon Y, Robotham JL, et al. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol. 2004;287(4):C817-833. doi: https://doi.org/10.1152/ajpcell.00139.2004Lien YC, Noel T, Liu H, et al. Phospholipase C-delta1 is a critical target for tumor necrosis factor receptor-mediated protection against adriamycin-induced cardiac injury. Cancer Res. 2006;66(8):4329-4338. doi: https://doi.org/10.1158/0008-5472.CAN-05-3424Lien YC, Noel T, Liu H, et al. Phospholipase C-delta1 is a critical target for tumor necrosis factor receptor-mediated protection against adriamycin-induced cardiac injury. Cancer Res. 2006;66(8):4329-4338. doi: https://doi.org/10.1158/0008-5472.CAN-05-3424Tappia PS, Asemu G, Aroutiounova N, Dhalla NS. Defective signal transduction of sarcolemmal phospholipase C in diabetic cardiomyopathy. Mol Cell Biochem. 2004;261(1-2):193-199. doi: https://doi.org/10.1023/b:mcbi.0000028756.31782.46Tappia PS, Asemu G, Aroutiounova N, Dhalla NS. Defective signal transduction of sarcolemmal phospholipase C in diabetic cardiomyopathy. Mol Cell Biochem. 2004;261(1-2):193-199. doi: https://doi.org/10.1023/b:mcbi.0000028756.31782.46Little PJ. GPCR responses in vascular smooth muscle can occur predominantly through dual transactivation of kinase receptors and not classical Gaq protein signalling pathways. Life Sci. 2013;92(20-21):951-956. doi: https://doi.org/10.1016/jJfs.2013.03.017Little PJ. GPCR responses in vascular smooth muscle can occur predominantly through dual transactivation of kinase receptors and not classical Gaq protein signalling pathways. Life Sci. 2013;92(20-21):951-956. doi: https://doi.org/10.1016/jJfs.2013.03.017Mikov M, Danic M, Pavlovic N, et al. Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics. Eur J Drug Metab Pharmacokinet. 2018;43(3):269-280. doi: https://doi.org/10.1007/s13318-017-0441-yMikov M, Danic M, Pavlovic N, et al. Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics. Eur J Drug Metab Pharmacokinet. 2018;43(3):269-280. doi: https://doi.org/10.1007/s13318-017-0441-yPollack RM, Donath MY, LeRoith D, Leibowitz G. Antiinflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care. 2016;39(2):S244-252. doi: https://doi.org/10.2337/dcS15-3015Pollack RM, Donath MY, LeRoith D, Leibowitz G. Antiinflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care. 2016;39(2):S244-252. doi: https://doi.org/10.2337/dcS15-3015Burgos-Moron E, Abad-Jimenez Z, Maranon AM, et al. Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: the battle continues. J Clin Med. 2019;8(9):1385. doi: https://doi.org/10.3390/jcm8091385Burgos-Moron E, Abad-Jimenez Z, Maranon AM, et al. Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: the battle continues. J Clin Med. 2019;8(9):1385. doi: https://doi.org/10.3390/jcm8091385Недосугова Л.В. Роль препаратов сульфонилмочевины в развитии сердечно-сосудистых осложнений при сахарном диабете 2 типа // Сахарный диабет. — 2013. — №2. — С. 26-35. doi: https://doi.org/10.14341/2072-0351-3753Nedosugova LV. Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus. Diabetes mellitus. 2013;(2):26-35. (In Russ.). doi: https://doi.org/10.14341/2072-0351-3753Choi SW, Ho CK. Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy? Redox Rep. 2018;23(1):1-24. doi: https://doi.org/10.1080/13510002.2017.1324381Choi SW, Ho CK. Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy? Redox Rep. 2018;23(1):1-24. doi: https://doi.org/10.1080/13510002.2017.1324381Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Scientific World J. 2014;2014:781857. doi: https://doi.org/10.1155/2014/781857Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Scientific World J. 2014;2014:781857. doi: https://doi.org/10.1155/2014/781857Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып. // Сахарный диабет. — 2019. — Т. 22. — №S1-1. — C. 1-144. doi: https://doi.org/10.14341/DM221S1Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes mellitus. 2019;22(S1-1):1-144. (In Russ.). doi: https://doi.org/10.14341/DM221S1Kalra S, Khandelwal D. Modern sulfonylureas strike back - exploring the freedom of flexibility. Eur Endocrinol. 2018;14(2):20-22. doi: https://doi.org/10.17925/EE.2018.14.220Kalra S, Khandelwal D. Modern sulfonylureas strike back - exploring the freedom of flexibility. Eur Endocrinol. 2018;14(2):20-22. doi: https://doi.org/10.17925/EE.2018.14.220Schrijnders D, Kleefstra N, Landman GW. Within-class differences of the sulfonylureas should be accounted for. Diabetologia. 2015;58(6):1374-1375. doi: https://doi.org/10.1007/s00125-015-3556-1Schrijnders D, Kleefstra N, Landman GW. Within-class differences of the sulfonylureas should be accounted for. Diabetologia. 2015;58(6):1374-1375. doi: https://doi.org/10.1007/s00125-015-3556-1Raju A, Shetty S, Cai B, D’Souza AO. Hypoglycemia incidence rates and associated health care costs in patients with type 2 diabetes mellitus treated with second-line linagliptin or sulfonylurea after metformin monotherapy. J Manag Care Spec Pharm. 2016;22(5):483-492. doi: https://doi.org/10.18553/jmcp.2016.22.5483Raju A, Shetty S, Cai B, D’Souza AO. Hypoglycemia incidence rates and associated health care costs in patients with type 2 diabetes mellitus treated with second-line linagliptin or sulfonylurea after metformin monotherapy. J Manag Care Spec Pharm. 2016;22(5):483-492. doi: https://doi.org/10.18553/jmcp.2016.22.5483Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533. doi: https://doi.org/10.1136/bmj.f4533Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533. doi: https://doi.org/10.1136/bmj.f4533Kalra S, Aamir AH, Raza A, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: a consensus statement. Indian J Endocrinol Metab. 2015;19(5):577-596. doi: https://doi.org/10.4103/2230-8210.163171Kalra S, Aamir AH, Raza A, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: a consensus statement. Indian J Endocrinol Metab. 2015;19(5):577-596. doi: https://doi.org/10.4103/2230-8210.163171Douros A, Yin H, Yu OHY, et al. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. Diabetes Care. 2017;40(11):1506-1513. doi: https://doi.org/10.2337/dc17-0595Douros A, Yin H, Yu OHY, et al. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. Diabetes Care. 2017;40(11):1506-1513. doi: https://doi.org/10.2337/dc17-0595Ohkuma T, Zoungas S, Jun M, et al. Intensive glucose-lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial. Diabetes Obes Metab. 2020;22(3):452-457. doi: https://doi.org/10.1111/dom.13878Ohkuma T, Zoungas S, Jun M, et al. Intensive glucose-lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial. Diabetes Obes Metab. 2020;22(3):452-457. doi: https://doi.org/10.1111/dom.13878Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019;105(5):1213-1223. doi: https://doi.org/10.1002/cpt.1307Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019;105(5):1213-1223. doi: https://doi.org/10.1002/cpt.1307Del Prato S, Nauck M, Duran-Garcia S, et al. Long-term glycemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17(6):581-590. doi: https://doi.org/10.1111/dom.12459Del Prato S, Nauck M, Duran-Garcia S, et al. Long-term glycemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17(6):581-590. doi: https://doi.org/10.1111/dom.12459CADTH Therapeutic Review. New drugs for type 2 diabetes: second-line therapy - science report. Therapeutic Review. 2017;4(1b):401. Available from: https://cadth.ca/sites/default/files/pdf/TR0012_T2D_Science_Report.pdfCADTH Therapeutic Review. New drugs for type 2 diabetes: second-line therapy - science report. Therapeutic Review. 2017;4(1b):401. Available from: https://cadth.ca/sites/default/files/pdf/TR0012_T2D_Science_Report.pdfGenere N, Montori VM. Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas. Ann Intern Med. 2018;168(2):JC8. doi: https://doi.org/10.7326/ACPJC-2018-168-2-008Genere N, Montori VM. Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas. Ann Intern Med. 2018;168(2):JC8. doi: https://doi.org/10.7326/ACPJC-2018-168-2-008Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: synopsis of the World Health Organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. Ann Intern Med. 2018;169(6):394-397. doi: https://doi.org/10.7326/M18-1149Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: synopsis of the World Health Organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. Ann Intern Med. 2018;169(6):394-397. doi: https://doi.org/10.7326/M18-1149American Diabetes Association. Pharmacologic аpproaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(1):S98-S110. doi: https://doi.org/10.2337/dc20-S009American Diabetes Association. Pharmacologic аpproaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(1):S98-S110. doi: https://doi.org/10.2337/dc20-S009World Health Organization. WHO model list of essential medicines. 20th list. 2017. 67 р. Available from: https://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdfWorld Health Organization. WHO model list of essential medicines. 20th list. 2017. 67 р. Available from: https://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf

The authors declare that there are no conflicts of interest present.